Saturday, 3 October 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· January 20, 2026

Taxes are going to change for retirees under Trump’s ‘big beautiful bill’. Here’s why you can’t afford to waste time

View original at finance.yahoo.com
Taxes are going to change for retirees under Trump’s ‘big beautiful bill’. Here’s why you can’t afford to waste time Samuel Corum/Getty Images Moneywise and Yahoo Finance LLC may earn commission or revenue through links in the content below…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Over 90% of Americans who shopped around and compared auto insurance rates from multiple lenders managed to save by switching carriers

    80% confidence
  • One asset will surge 400% in a year

    80% confidence
  • A 7-step plan works every single time to kill debt, get rich in America, and anyone can do it

    80% confidence
  • 8 repeatable money rules were used to turn $9,800 into a $150B fortune, and these rules work for anyone

    80% confidence
  • Nearly 50% of Americans are making 1 big Social Security mistake

    80% confidence
  • The OBBBA includes a $1.1 trillion cut on federal spending for the Affordable Care Act and Medicaid across the next decade

    80% confidence
  • Nearly one in eight Americans rely on SNAP benefits

    80% confidence
  • 53% of American adults strongly or somewhat oppose Trump's budget

    80% confidence
  • An estimated 11.8 million people will lose health coverage by 2034 due to OBBBA cuts, revised eligibility requirements, additional charges and new limitations

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com